Prometheus Biosciences Inc (RXDX)

199.92 +0.00 (+0.00%)
Close USD Disclaimer

Prometheus Biosciences Inc Company Profile

Equity Type
Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in a Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn’s disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein-coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD and inflammatory and fibrotic diseases. Prometheus Biosciences, Inc. was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. The company was founded in 1995 and is based in San Diego, California. As of June 16, 2023, Prometheus Biosciences, Inc. operates as a subsidiary of Merck & Co., Inc.
Contact Information
San Diego,92121 United States
858 422 4300

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles